Madison Williams Analysts Initiate Coverage on Adolor (ADLR)
Research analysts at Madison Equities Williams on the actions initiated coverage Adolor (NASDAQ: ADLR) in a research note to investors Wednesday. Analysts define a "buy" rating and a target price of $ 5.00 on the stock.
In addition, the Summer Street analysts initiated the shares of Adolor coverage in a research note to investors Monday. They set a "buy" rating and a $ 6.00 price target on the stock. In addition, analysts Brean Murray raised its price target on shares of Adolor $ 4.00 to $ 5.00 in a research note to investors Wednesday, June 15. They now have a "buy" rating on the stock.
Shares of Adolor open at 2.39 on Thursday. Adolor has a 52 week low of $ 1.01 and a week high $ 2.83 52. The stock of 50 days moving average is $ 1.94 and its 200-day moving average is $ 1.56. The company has a market capitalization of 111.0 million.
Adolor last announced its quarterly results Thursday, April 28. The company announced ($ 0.16) earnings per share (EPS) for the previous quarter, the estimate of Thomson Reuters consensus meeting ($ 0.16) EPS. During the same quarter last year, the company posted ($ 0.21) per share. The companyâ € ™ s quarterly revenue grew 41.50% on a year by year.On average, analysts predict that Adolor will post $ -0.34 EPS next quarter.
Adolor Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription pain management. The Companyââ, ¬ â "¢ s product Entereg is indicated to accelerate upper and lower gastrointestinal (GI) recovery after bowel surgery partial resection of small or large with primary anastomosis. The Company also has a number of product candidates various stages of clinical and preclinical development. The company collaborates with Pfizer Inc.(Pfizer) in the clinical development of two compounds delta opioid receptor agonist: ADL5859 and ADL5747, for the treatment of pain. The Company is also ADL7445 and ADL5945 tests clinically to treat opioid bowel dysfunction (OBD), a condition that often results from chronic use of opioid analgesics to treat persistent pain. Its other product candidates are in preclinical development for the treatment of moderate to severe pain and other disorders of the central nervous system.
Stay on top of analysts' coverage with American Banking & Market News "daily newsletter that provides a concise list of" upgrades, analysts analysts analysts downgrades and changes target price for each day. Click here to register.
Small Intestine Resection - News
Tissue-engineered small intestine (TESI) has successfully been used to rescue Lewis rats after massive small bowel resection. In this study, we transitioned the technique to a mouse model, allowing investigation of the processes involved during TESI
The Company’s product ENTEREG, is indicated to accelerate upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. The Company also has a number of product candidates in
This damage causes tissue that is similar to the lining of the small intestine to replace the normal tissue lining of the esophagus. Barrett's esophagus is a silent condition because there are no signs or symptoms associated with it.
Adolor's first approved product in the United States is ENTEREG(R) (alvimopan), which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis.
In most cases onset is in adolescence or young adult life and up to 80% of patients with CD have to face surgical bowel resection at some point due to complications such as stricture and mechanical bowel obstruction. According to Dr. Wilson,
Entereg Drug Review - Entereg Side Effects and Dosage | Drugs Mega ...
Drug Name: Entereg
Generic Name: alvimopan
Group: Peripheral opioid receptor antagonists
Introduction and quick information:
Entereg is specifically indicated to accelerate the recovery time of the upper and lower digestive tract following partial surgical resection of small or large bowel with primary anastomosis.
Entereg is a white to light tan colored powder. Entereg is a drug prescribed oral peripherally acting.It is an antagonist of mu-opioid receptors. This means Entereg (alvimopan) is opposed to the side effects of opioids on gastrointestinal motility and release by binding to viable gastrointestinal tract mu-opioid receptors.
Entereg decreases side effects caused by narcotic medications that are used to reduce pain due to surgery.
Narcotic drugs can lead to bloating, vomiting, nausea and constipation. Side effects can delay recovery in individuals undergoing gastrointestinal surgery. It works by treating these side effects, without interfering with the mechanism of pain medicine narcotics.Entereg help in quick recovery of the stomach and intestinal function, after undergoing gastrointestinal surgery.
Is it FDA approved?
Entereg was approved by the FDA (Food and Drug Administration) to treat constipation and other gastrointestinal problems since May 20, 2008. "
Use and benefits of Entereg:
Entereg (alvimopan) is used for short-term use while you are hospitalized. You will not receive the drug for more than two weeks during the period when you are in hospital.You will not be recommended Entereg more after your discharge.
Entereg (alvimopan) is used for the recovery of the colon after if you have had bowel surgery. This medicine helps to have solid food and contributes to regular bowel movements. Entereg falls into the group of drugs called receptor antagonists peripherally acting mu-opioid. It works by protecting the intestines, the effects of narcotic drugs that are used to treat pain after surgery.
Entereg Side effects:
Side effects are associated with each drug you can have minor side effects or no side effects at all.
Small Intestine Resection - Bookshelf
Operative anatomy
Small Bowel Resection and Anastomosis Small bowel resection is performed when a ... Carcinoma of the small intestine is rare. Resection for carcinoma should ...The Journal of nutrition
Nutritional Adaptation after Small Bowel Resection in Rats1'2 ELEANOR A. YOUNG AND ELLIOT WESER Section of Gastrocnterology, Department of Medicine, ...Gastrointestinal surgery, pathophysiology and management
SHORT BOWEL SYNDROME The small intestine is about 6 meters in length. Massive small bowel resection implies resection of more than 50% of the bowel, ...Bulletin of the Johns Hopkins Hospital
Resections of 75 per cent and even more of the total small intestine may be survived, but such animals are not liable to show a true recovery, ie, ...Surgery, gynecology & obstetrics
On the other hand a large number of small intestinal growths escape ... patient be not subjected to the needless risk of an extensive intestinal resection, ...Find An Article Directory
Small bowel resection: MedlinePlus Medical Encyclopedia
Small bowel resection is surgery to remove part or all of your small bowel. ... The small bowel is also called the small intestine. Most digestion (breaking down and ...
Small Bowel Resection - procedure, recovery, blood, tube ...
A small bowel resection may be performed to treat the following conditions: ... Cancer of the small intestine is a rare cancer in which malignant ...
Small bowel resection - Overview
Small bowel resection - Overview, Small bowel resection is surgery to remove part or...
What is Small bowel resection?
Small bowel resection is surgery to remove part of your small bowel, which is located between your stomach and large bowel (large intestine) ...
Small Bowel Resection: Details, Preparation & Recovery: BCM ...
A small bowel resection is the surgical removal of a diseased section ... The small bowel resection can be performed laparoscopically using long, thin instruments ...